Prescribed Medicinal Cannabis for the Treatment of Chronic Pain Comorbid with Depression: Real World Evidence from Project Twenty21

Alkyoni Athanasiou-Fragkouli, Michael T Lynskey, A. Schlag, David J Nutt
{"title":"Prescribed Medicinal Cannabis for the Treatment of Chronic Pain Comorbid with Depression: Real World Evidence from Project Twenty21","authors":"Alkyoni Athanasiou-Fragkouli, Michael T Lynskey, A. Schlag, David J Nutt","doi":"10.21926/obm.icm.2402032","DOIUrl":null,"url":null,"abstract":"Chronic pain is one of the most common conditions for which people seek treatment with cannabis-based medicinal products (CBMPs) and there is mounting real world evidence that CBMPs are safe and effective in treating pain. Many people with chronic pain also experience major depression and it is unknown whether pain patients with major depression derive equal benefit from CBMPs as those who are not depressed since comorbidities are usually an exclusion factor in RCTs. This study aimed to investigate whether patients with chronic pain with and without co-morbid depression experience the same improvement in pain and quality of life outcomes after three months of medical cannabis treatment. Data were derived from Project Twenty21 (T21), one of the largest observational studies in medicinal cannabis in the UK. Baseline data were available for 1816 chronic pain patients and three-month follow-up data were available for 1058 of these patients. Logistic regression models were used to examine the relationship between chronic pain and comorbid depression after three months of medical cannabis treatment controlling for sociodemographic factors. Prescribed cannabis was associated with marked reductions in pain severity and interference and with improvements in aspects of general health and quality of life. A substantial portion (23.4%) of chronic pain patients reported comorbid depression. Patients with comorbid depression reported more pain interference at baseline (mean = 7.5 vs 6.8, p < 0.01) while there was no significant difference for pain severity (mean = 5.9 vs 6.0, p > 0.05). Depression status did not predict reduction in pain severity and interference at three months, while baseline scores, age and number of total comorbidities predicted some treatment outcomes. These results indicate that comorbid depression should not be a barrier to accessing treatment with CBMPs for chronic pain patients.","PeriodicalId":413918,"journal":{"name":"OBM Integrative and Complementary Medicine","volume":"3 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OBM Integrative and Complementary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21926/obm.icm.2402032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic pain is one of the most common conditions for which people seek treatment with cannabis-based medicinal products (CBMPs) and there is mounting real world evidence that CBMPs are safe and effective in treating pain. Many people with chronic pain also experience major depression and it is unknown whether pain patients with major depression derive equal benefit from CBMPs as those who are not depressed since comorbidities are usually an exclusion factor in RCTs. This study aimed to investigate whether patients with chronic pain with and without co-morbid depression experience the same improvement in pain and quality of life outcomes after three months of medical cannabis treatment. Data were derived from Project Twenty21 (T21), one of the largest observational studies in medicinal cannabis in the UK. Baseline data were available for 1816 chronic pain patients and three-month follow-up data were available for 1058 of these patients. Logistic regression models were used to examine the relationship between chronic pain and comorbid depression after three months of medical cannabis treatment controlling for sociodemographic factors. Prescribed cannabis was associated with marked reductions in pain severity and interference and with improvements in aspects of general health and quality of life. A substantial portion (23.4%) of chronic pain patients reported comorbid depression. Patients with comorbid depression reported more pain interference at baseline (mean = 7.5 vs 6.8, p < 0.01) while there was no significant difference for pain severity (mean = 5.9 vs 6.0, p > 0.05). Depression status did not predict reduction in pain severity and interference at three months, while baseline scores, age and number of total comorbidities predicted some treatment outcomes. These results indicate that comorbid depression should not be a barrier to accessing treatment with CBMPs for chronic pain patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
处方药用大麻用于治疗合并抑郁症的慢性疼痛:来自 "二十一世纪项目 "的真实证据
慢性疼痛是人们寻求大麻药用产品(CBMPs)治疗的最常见疾病之一,越来越多的现实证据表明 CBMPs 在治疗疼痛方面安全有效。许多慢性疼痛患者同时也患有重度抑郁症,而患有重度抑郁症的疼痛患者是否与没有抑郁症的患者一样能从 CBMPs 中获益尚不得而知,因为合并症通常是 RCTs 的排除因素。本研究旨在调查合并抑郁症和未合并抑郁症的慢性疼痛患者在接受三个月的医用大麻治疗后,在疼痛和生活质量方面是否有同样的改善。数据来源于二十一世纪项目(T21),该项目是英国最大的药用大麻观察性研究之一。该项目获得了 1816 名慢性疼痛患者的基线数据,并获得了其中 1058 名患者三个月的随访数据。使用逻辑回归模型研究了医用大麻治疗三个月后慢性疼痛和合并抑郁症之间的关系,并对社会人口因素进行了控制。处方大麻明显减轻了疼痛的严重程度和干扰,改善了一般健康状况和生活质量。相当一部分(23.4%)慢性疼痛患者报告合并有抑郁症。合并抑郁症的患者在基线时报告了更多的疼痛干扰(平均值 = 7.5 vs 6.8,p < 0.01),而疼痛严重程度没有显著差异(平均值 = 5.9 vs 6.0,p > 0.05)。抑郁状况并不能预测三个月后疼痛严重程度和干扰程度的减轻,而基线评分、年龄和合并症总数则能预测一些治疗结果。这些结果表明,合并抑郁症不应成为慢性疼痛患者接受 CBMPs 治疗的障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Filial Piety Discrepancy and Wellbeing among Older Chinese Immigrants Living in Canada: The Role of Acculturation and Living Arrangement Applied Pragmatic Functional Contextualism: A New Epistemological and Theoretical Framework for Applied Mental Health Research Eryngium carlinae Extract and Exercise Improve Blood Lipid Profile and Skeletal Muscle Function in Obese Rats Scoping Review of Nutraceuticals Use in Mediterranean Diet Therapeutic Termination of Pregnancy and Paternal Mental Outcomes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1